ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSKBAHRIS..MTNORSMESM..................*JBDM Ver 0.1.63 (23 May 2017) - 2999001/02694972CORRECTED EUROPEAN PATENT SPECIFICATIONB8B120170816W173deBibliographieenBibliographyfrBibliographieEP12716858.1201204042013100220141020enenen201161471678 P20110404US201261590787 P20120125US2017081620173320140212201407201706212017252017011220170816201733G01N 33/574 20060101AFI20121025BHEP deVERFAHREN ZUR VORHERSAGE UND VERBESSERUNG DER ÜBERLEBENSZEIT VON MAGENKREBSPATIENTENenMETHODS FOR PREDICTING AND IMPROVING THE SURVIVAL OF GASTRIC CANCER PATIENTSfrPROCÉDÉS POUR PRÉDIRE ET AMÉLIORER LA SURVIE DE PATIENTS ATTEINTS DE CANCER GASTRIQUEWO-A1-2011/008990BACHLEITNER-HOFMANN T. ET AL.: "Stimulation of epidermal growth factor (EGFR) or HER-3 mediates resistance to MET tyrosine kinase inhibition in MET-amplified gastric cancer cells", PROC. AM. ASS. CANCER RES. ANN. MEETING, vol. 49, April 2008 (2008-04), page 1186, XP002678285, & 99TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; SAN DIEGO, CA, USA; APRIL 12 -16, 2008BACHLEITNER-HOFMANN T. ET AL.: "Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET inhibition", CLIN. CANCER RES., vol. 17, no. 1, 1 January 2011 (2011-01-01), pages 122-133, XP55030286,MUKOHARA T. ET AL.: "Foretinib (GSK1363089) inhibits growth of gastric cancer cell lines through blockade of inter-receptor tyrosine kinases networks", EUR. J. CANCER, vol. 8, no. 7, #109, November 2010 (2010-11), page 42, XP027497797,TABERNERO J. ET AL.: "Integration of targeted therapies", EUR. J. CANCER, vol. 7, no. 2, #305, September 2009 (2009-09), page 74, XP026689064,BACHLEITNER-HOFMANN T. ET AL.: "HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells", MOL. CANCER THER., vol. 7, no. 11, November 2008 (2008-11), pages 3499-3508, XP55020686,CORSO S. ET AL.: "Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition", MOL. CANCER, vol. 9, no. 1, 26 May 2010 (2010-05-26), page 121, XP021077869,PENTHEROUDAKIS G. ET AL.: "Incorporation of Targeted Agents in the Management of Patients with Advanced Gastric Cancer", CURR. MED. CHEM., vol. 18, no. 11, 1 April 2011 (2011-04-01) , pages 1629-1639, XP002678286,KIM P. ET AL.: "Highly sensitive proximity mediated immunoassay reveals HER2 status conversion in the circulating tumor cells of metastatic breast cancer patients", PROTEOME SCIENCE, vol. 9, no. 1, 15 December 2011 (2011-12-15), page 75, XP55030160,KIM, Phillip28 ExeterIrvine, CA 92612USSINGH, Sharat8171 Top of the Morning WayRancho Santa Fe, CA 92127USPierian Holdings, Inc.101671256N408155EP405 Duke Drive, Suite 240Franklin, TN 37067USJ A Kemp10166966614 South Square Gray's InnLondon WC1R 5JJGBALATBEBGCHCYCZDEDKEEESFIFRGBGRHRHUIEISITLILTLULVMCMKMTNLNOPLPTRORSSESISKSMTRBA20131002ME20131002US201203220620120404enWO20121387852012101120124120140212201407